Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TT-01488 in B-Cell Malignancies
NCT05683717Phase 1Recruiting
- Sponsor
- TransThera Biosciences
- Start
- Mar 2023
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of TT-01488 in B cell malignancies (2 arms), sponsored by TransThera Biosciences. Primary endpoints: Dose-Limiting Toxicity at 28 days, Dose Recommended for Dose Expansion at 3 years and 1 more. Started Mar 2023; status: recruiting.
02
Drugs
TT-01488
03
Conditions
B cell malignancies
Beyond the preview
Go deeper on NCT05683717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05683717.